Emerald Acquisition Ltd. bought a new position in Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) during the second quarter, Holdings Channel reports. The fund bought 21,620 shares of the specialty pharmaceutical company’s stock, valued at approximately $839,000. Emerald Acquisition Ltd. owned 0.14% of Eagle Pharmaceuticals at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the company. LaSalle Street Capital Management LLC purchased a new stake in shares of Eagle Pharmaceuticals during the second quarter worth about $304,000. Columbus Circle Investors purchased a new stake in shares of Eagle Pharmaceuticals during the second quarter worth about $306,000. Royal Bank of Canada boosted its stake in shares of Eagle Pharmaceuticals by 64.3% in the first quarter. Royal Bank of Canada now owns 11,934 shares of the specialty pharmaceutical company’s stock worth $484,000 after buying an additional 4,670 shares during the period. Swiss National Bank boosted its stake in shares of Eagle Pharmaceuticals by 10.2% in the second quarter. Swiss National Bank now owns 15,100 shares of the specialty pharmaceutical company’s stock worth $586,000 after buying an additional 1,400 shares during the period. Finally, California State Teachers Retirement System boosted its stake in shares of Eagle Pharmaceuticals by 2.1% in the second quarter. California State Teachers Retirement System now owns 18,565 shares of the specialty pharmaceutical company’s stock worth $720,000 after buying an additional 385 shares during the period.
Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) traded up 0.4263% on Thursday, reaching $63.6301. 104,945 shares of the company traded hands. The firm has a 50 day moving average of $63.82 and a 200-day moving average of $49.28. Eagle Pharmaceuticals Inc. has a one year low of $33.02 and a one year high of $102.48. The stock has a market capitalization of $994.92 million, a PE ratio of 326.3082 and a beta of 1.16.
Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.09. The firm earned $40.90 million during the quarter, compared to analysts’ expectations of $43.55 million. Eagle Pharmaceuticals had a net margin of 3.45% and a return on equity of 3.44%. The business’s revenue for the quarter was up 581.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.53) earnings per share. On average, analysts anticipate that Eagle Pharmaceuticals Inc. will post $3.21 EPS for the current year.
Several equities research analysts have weighed in on EGRX shares. Zacks Investment Research cut shares of Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Friday, July 22nd. Mizuho restated a “neutral” rating and issued a $47.00 price objective (up previously from $37.80) on shares of Eagle Pharmaceuticals in a research report on Tuesday, July 26th. RBC Capital Markets restated an “outperform” rating and issued a $80.00 price objective (up previously from $78.00) on shares of Eagle Pharmaceuticals in a research report on Thursday, September 22nd. Finally, TheStreet upgraded shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 9th. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $90.24.
In other news, major shareholder Proquest Investments Iv, L.P. sold 22,100 shares of the stock in a transaction dated Friday, September 30th. The shares were sold at an average price of $70.06, for a total value of $1,548,326.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 18.80% of the stock is currently owned by insiders.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).
Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals Inc. (NASDAQ:EGRX).
Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.